PDF herunterladen
Frauenheilkunde up2date 2013; 7(5): 375-385
DOI: 10.1055/s-0033-1346683
Gynäkologische Endokrinologie und Reproduktionsmedizin
Georg Thieme Verlag KG Stuttgart · New York

Hormontherapie bei Patientinnen mit gynäkologischen Malignomen

Claus Lattrich
,
Susanne Schüler
,
Olaf Ortmann
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. Oktober 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik
Kernaussagen

Eine HT ist nach Behandlung einer Brust-, Endometrium- oder Ovarialkarzinomerkrankung grundsätzlich kontraindiziert. In Ausnahmefällen und nach individueller Beratung der Patientin über mögliche Risiken und Nutzen einer HT kann sie im Einzelfall zur Therapie klimakterischer Beschwerden erwogen werden. Die Patientin sollte auf jeden Fall über den möglichen Einsatz nichthormoneller Therapien aufgeklärt werden. Besonderes Augenmerk ist der Selbstmedikation der Patientin zu widmen, da komplementäre oder alternative Therapieansätze bei der Karzinombehandlung kontraindiziert oder unsicher sein können.

 

  • Literatur

  • 1 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. S3-Leitlinie „Hormontherapie in der Peri- und Postmenopause“. http://www.awmf.org/leitlinien/detail/ll/015-062.html
    Google Scholar
  • 2 The North American Menopause Society. Menopause Practice: A Clinicianʼs Guide. 4th ed. Mayfield Heights, OH/USA: NAMS; 2010
    Google Scholar
  • 3 Ash P. The influence of radiation on fertility in man. Br J Radiol 1980; 53: 271-278
    CrossrefGoogle Scholar
  • 4 Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67: 326-330
    Google Scholar
  • 5 Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987; 26: 169-177
    CrossrefGoogle Scholar
  • 6 Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36: 189-191
    CrossrefGoogle Scholar
  • 7 Gerbaldo D, Ferraiolo A, Croce S et al. Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women. Maturitas 1991; 13: 269-274
    CrossrefGoogle Scholar
  • 8 Eeles RA, Tan S, Wiltshaw E et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Br Med J 1991; 302: 259-262
    CrossrefGoogle Scholar
  • 9 Habeshaw T, Pinion SB. The incidence of persistent functioning endometrial tissue following successful radiotherapy for cervical carcinoma. Int J Gynecol Cancer 1992; 2: 332-335
    CrossrefGoogle Scholar
  • 10 DiSaia PJ, Grosen EA, Kurosaki T et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996; 174: 1494-1498
    CrossrefGoogle Scholar
  • 11 Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996; 23 (Suppl.) S37-S45
    CrossrefGoogle Scholar
  • 12 Chapman JA, DiSaia PJ, Osann K et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175: 1195-1200
    CrossrefGoogle Scholar
  • 13 Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65: 89-93
    CrossrefGoogle Scholar
  • 14 Natrajan PK, Soumakis K, Gambrell jr. RD. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999; 181: 288-295
    CrossrefGoogle Scholar
  • 15 Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17: 1482-1487
    Google Scholar
  • 16 Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. Cancer 1999; 86: 1013-1018
    CrossrefGoogle Scholar
  • 17 Beckmann MW, Jap D, Djahansouzi S et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density, and recurrence rates. Oncology 2001; 60: 199-206
    CrossrefGoogle Scholar
  • 18 OʼMeara ES, Rossing MA, Daling JR et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754-762
    CrossrefGoogle Scholar
  • 19 Col NF, Hirota LK, Orr RK et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-2363
    Google Scholar
  • 20 Suriano KA, McHale M, McLaren CE et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001; 97: 555-560
    CrossrefGoogle Scholar
  • 21 Ursic-Vrscaj M, Bebar S, Zakelj MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause 2001; 8: 70-75
    CrossrefGoogle Scholar
  • 22 Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Womenʼs Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701-1712
    CrossrefGoogle Scholar
  • 23 Wang PH, Chang C. Androgens and ovarian cancers. Eur J Gynecol Oncol 2004; 25: 157-163
    Google Scholar
  • 24 Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-455
    CrossrefPubMedGoogle Scholar
  • 25 von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J National Cancer Inst 2005; 97: 533-535
    CrossrefGoogle Scholar
  • 26 Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005; 6: 687-695
    CrossrefGoogle Scholar
  • 27 Rebbeck TR, Friebel T, Wagner T et al. Group Prose Study: Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810
    CrossrefGoogle Scholar
  • 28 Barakat RR, Bundy BN, Spirtos NM et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 587-592
    CrossrefGoogle Scholar
  • 29 Mascarenhas C, Lambe M, Bellocco R et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 2006; 119: 2907-2915
    CrossrefGoogle Scholar
  • 30 Kotsopoulos J, Lubinski J, Neuhausen SL et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006; 100: 83-88
    CrossrefGoogle Scholar
  • 31 Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol/ESMO 2006; 17: 584-587
    Google Scholar
  • 32 Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. J Am Med Assoc 2006; 295: 2057-2071
    CrossrefGoogle Scholar
  • 33 de Bock GH, van der Hage JA, Putter H et al. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 2006; 42: 351-356
    CrossrefGoogle Scholar
  • 34 Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710
    CrossrefGoogle Scholar
  • 35 Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J National Cancer Instit 2008; 100: 475-482
    Google Scholar
  • 36 Kenemans P, Bundred NJ, Foidart JM et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-146
    CrossrefPubMedGoogle Scholar
  • 37 Morch LS, Lokkegaard E, Andreasen AH et al. Hormone therapy and ovarian cancer. J Am Med Assoc 2009; 302: 298-305
    CrossrefGoogle Scholar
  • 38 Rada G, Capurro D, Pantoja T et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; (9) CD004923
    Google Scholar
  • 39 Walker EM, Rodriguez AI, Kohn B et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 2010; 28: 634-640
    CrossrefGoogle Scholar
  • 40 Chuery AC, Speck NM, de Moura KF et al. Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. Clin Experiment Obstet Gynecol 2011; 38: 143-145
    Google Scholar
  • 41 Pfeiler G, Glatz C, Konigsberg R et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-344
    CrossrefGoogle Scholar
  • 42 Griesser H, Skonietzki S, Fischer T et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012; 71: 360-368
    CrossrefGoogle Scholar
  • 43 Haring J, Schuler S, Lattrich C et al. Role of estrogen receptor beta in gynecological cancer. Gynecol Oncol 2012; 127: 673-676
    CrossrefGoogle Scholar
  • 44 Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012; 285: 1397-1402
    CrossrefGoogle Scholar
  • 45 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
    CrossrefGoogle Scholar
  • 46 Fahlen M, Fornander T, Johansson H et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013; 49: 52-59
    CrossrefPubMedGoogle Scholar
  • 47 Maligne Ovarialtumore: Diagnostik, Therapie und Nachsorge. http://www.awmf.org/leitlinien/detail/ll/032-035OL.html Stand: 30.06.2013
    Google Scholar
  • 48 Sekar H, Singhal T, Holloway D, Rymer J. The use of hormone therapy and its alternatives in women with a history of hormone dependent cancer. Menopause Int 2013; 19: 37-42
    Google Scholar